Arbaclofen, an investigational medicine for fragile X syndrome, was found to improve certain aspects of behavior in about half…
Articles by Margarida Maia, PhD
Nova Mentis has received the green light from the U.S. Drug Enforcement Administration (DEA) to ship psilocybin (NM-1001) into…
Wearable motion sensors someday may help doctors diagnose fragile X syndrome and similar disorders based on the way people walk, a…
Nova Mentis is seeking orphan drug designation from the European Medicines Agency (EMA) for psilocybin, its investigational therapy for…
COVID-19 lockdowns posed additional challenges for mothers and their children — from toddlers to teens — with fragile X syndrome,…